Studies on anabolic steroidsII—gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man

Massé, Robert; Bi, Honggang; Ayotte, Christiane; Dugal, Robert

doi:10.1002/bms.1200180612

Cited by 35 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, trends in the comparison of the groups’ height velocity increment did not become statistically significant. Growth acceleration is comparable to previous reports on the use of testosterone [3, 4]or oxandrolone [5, 6, 7, 8, 9, 10]in CDG. Along with comparable growth, gonadarche advanced faster in the testosterone-50-mg group than in the oxandrolone group.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Androgen Therapy in Constitutional Delay of Growth

Lampit

Hochberg

2003

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: Two modalities of androgen therapy prevail in the treatment of constitutional delay of growth (CDG): monthly injections of testosterone or daily tablets of the non-aromatizable oxandrolone. The present study was undertaken to prospectively compare both compounds and dose. Methods: Thirty patients with CDG were the subjects of this study. The protocol required that they all be at age 12–14 years with a bone age delay of more than 2 ‘years’, height less than –2 SDS and growth velocity less than –0.5 SDS. The subjects were at a Tanner stage 1 or 2 and testicular volume were no larger than 4 ml. They were randomly assigned into 3 treatment groups: group 1 patients received monthly injections of 25 mg testosterone propionate-enanthate; group 2 patients received monthly injections of 50 mg testosterone propionate-enanthate; group 3 patients received oral oxandrolone at a weekly dose of 0.7 mg/kg. Treatment was given for a period of 6 months and follow-up commenced 6 months later and yearly thereafter for 2 years. Results: Height velocity and height increased significantly only in groups 2 and 3. Bone age advanced most in group 2. Puberty progressed faster in that group as compared with group 3. The predicted adult height before and 2 years after completion of treatment remained unchanged in the two testosterone groups. It increased significantly in the oxandrolone group from a mean 169.8 cm before therapy to a mean 177.5 cm 2 years after completion of therapy. Peak GH levels were significantly higher on both testosterone 50 mg and oxandrolone, as compared to pretreatment levels. The increment was significantly greater in group 2 as was the increment in serum IGF-1 and IGFBP3. Conclusions: These results imply that 6 months of testosterone injections at a dose of 50 mg, but not 25 mg, is an effective and safe treatment for patients with CDG, with no considerable impact on final height prediction. On the other hand, daily oxandrolone treatment, starting at age 12–14 years, may increase the predicted final adult height.

show abstract

Section: Discussionsupporting

confidence: 77%

“…It is almost completely absorbed, reaches peak blood levels at 1 h and is eliminated with a half-life of 9.4 h [2]. In distinct contrast to testosterone, oxandrolone undergoes little metabolism or conjugation and is not aromatized into estrogen [3]. …”

Section: Introductionmentioning

confidence: 99%

Androgen Therapy in Constitutional Delay of Growth

Lampit

Hochberg

2003

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Reduction of C-3 keto group and hydroxylation at C-6 position are also proposed. M7 concerns steroids with heteroatom at steroidal structure (as in oxandrolone molecule [20,21]) which directs metabolism to C-/D-rings leading to the 17-epimerized, 16-hydroxylated and dehydration products.…”

Section: Proposed Metabolism Scheme For Steroids With 5˛-androstan-3-mentioning

confidence: 99%

Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine

Fragkaki

Angelis

Tsantili‐Kakoulidou

et al. 2009

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…less than 5% for probenecid or 51% for ethamivan), their chromatographic behavior and/or instability of their derivatives (e.g. 17α‐epioxandrolone) 23. As explained before, extracts analysed by GC/MS/MS were prepared using the routine extraction procedure, just as those screened by conventional GC/MS 24, 25.…”

Section: Resultsmentioning

confidence: 99%

Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry

et al. 2002

View full text Add to dashboard Cite

A fast and sensitive method for the comprehensive screening of anabolic agents and other banned doping substances using gas chromatography/tandem mass spectrometry (GC/MS/MS) with an external ionization ion trap mass spectrometer is presented. The method takes advantage of the resolving power of MS/MS to eliminate background interferences, thus speeding up the chromatographic analysis. For each compound, different fragmentation reactions were studied and their collision energies optimized to obtain the best sensitivity in terms of their signal-to-noise ratio (S/N). A dramatic reduction in overall analysis time was achieved compared with other common approaches. More than 50 substances could finally be monitored in less than 7.4 min with detection limits (S/N >3) lower than 0.5 ng ml(-1) for most of the compounds with special sensitivity requirements according to the International Olympic Committee (IOC). A validation procedure for qualitative analysis was performed. The selectivity of the method showed that no interfering peaks were observed at the retention time of the analytes. Good intermediate precision, below 25% for most of the compounds, and robustness were observed. The optimized method was successfully applied to analyse more than 100 real human urine samples with optimum sensitivity and specificity rates.

show abstract

Studies on anabolic steroidsII—gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man

Cited by 35 publications

References 23 publications

Androgen Therapy in Constitutional Delay of Growth

Androgen Therapy in Constitutional Delay of Growth

Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine

Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry

Contact Info

Product

Resources

About